Drugs / 610
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05584306 | Dec 2021 → Sep 2023 | asthma | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 610 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05584306 ↗ |
| Action | Inhibit | “Anti-IL-5” NCT05584306 ↗ |
| Modality | Monoclonal antibody | “Recombinant Anti-IL-5 Humanized Monoclonal Antibody Therapy” NCT05584306 ↗ |
| Route | Subcutaneous | “610 30 mg administered subcutaneously every 4 weeks” NCT05584306 ↗ |
| Target | IL5 | “Recombinant Anti-IL-5 Humanized Monoclonal Antibody Therapy” NCT05584306 ↗ |